Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2004 Sep;63(9):1069–1074. doi: 10.1136/ard.2003.012914

A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment

P Durez 1, T Nzeusseu 1, B Lauwerys 1, D Manicourt 1, P Verschueren 1, R Westhovens 1, J Devogelaer 1, F Houssiau 1
PMCID: PMC1755125  PMID: 15308515

Abstract

Objectives: To compare the short term clinical and biological effects of intravenous (IV) pulse methylprednisolone (MP) and infliximab (IFX) in patients with severe active rheumatoid arthritis (RA) despite methotrexate (MTX) treatment.

Methods: Patients with active RA despite MTX treatment were randomly allocated to receive a single IV infusion of MP (1 g) or three IV infusions of IFX (3 mg/kg) on weeks 0, 2, and 6. Patients were "blindly" evaluated for disease activity measures. Quality of life (QoL) was evaluated through the SF-36 health survey. Serum matrix metalloproteinase-3 (MMP-3) titres were measured at baseline, weeks 2 and 6.

Results: Compared with baseline, significant improvement was noted in all activity measures, including serum C reactive protein (CRP) titres, in the IFX group only. At week 14, 6/9 (67%) and 4/9 (44%) IFX patients met the ACR20 and 50 response criteria, while this was the case in only 1/12 (8%) and 0/12 (0%) MP patients, respectively (p<0.05). None of the QoL scales improved with MP treatment, whereas some did so in the IFX group. Serum MMP-3 titres significantly decreased (41% drop) at week 6 in the IFX group, while no changes were seen in patients given MP.

Conclusion: This short term randomised comparative study demonstrates that TNF blockade is better than MP pulse therapy in a subset of patients with severe refractory RA, with improvement in not only clinical parameters of disease activity but also biological inflammatory indices, such as serum CRP and MMP-3 titres.

Full Text

The Full Text of this article is available as a PDF (155.3 KB).

Figure 1.

Figure 1

Open in a new tab

 Disease activity measures in patients treated with MP pulse (circles) or IFX (squares). Results are presented as means (SEM). Asterisks placed below the squares refer to between-groups p values. Asterisks placed above the squares or the circles refer to intragroup p values. *p<0.05; **p<0.005; ***p<0.0005.

Figure 2.

Figure 2

Open in a new tab

 American College of Rheumatology (ACR) 20 and 50 response rates at week 14 in patients treated with IFX or MP. Owing to missing TJC values, the ACR response rates could be calculated for only 12 and 9 patients from the MP and IFX group, respectively.

Figure 3.

Figure 3

Open in a new tab

 Serum IL6 and MMP-3 titres measured in patients treated with IFX or MP. Results are means (SEM). Significant between-groups and intragroup differences are indicated by corresponding p values.

Figure 4.

Figure 4

Open in a new tab

 Disease activity measures in patients randomised to the MP group and given open access to IFX treatment, immediately before and 2 weeks after the first IFX injection. Results are means (SEM). Significant differences are indicated by corresponding p values.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. doi: 10.1002/art.1780310302. [DOI] [PubMed] [Google Scholar]
  2. Boers M., Verhoeven A. C., Markusse H. M., van de Laar M. A., Westhovens R., van Denderen J. C., van Zeben D., Dijkmans B. A., Peeters A. J., Jacobs P. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997 Aug 2;350(9074):309–318. doi: 10.1016/S0140-6736(97)01300-7. [DOI] [PubMed] [Google Scholar]
  3. Brennan F. M., Browne K. A., Green P. A., Jaspar J. M., Maini R. N., Feldmann M. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br J Rheumatol. 1997 Jun;36(6):643–650. doi: 10.1093/rheumatology/36.6.643. [DOI] [PubMed] [Google Scholar]
  4. Buttgereit F., da Silva J. A. P., Boers M., Burmester G-R, Cutolo M., Jacobs J., Kirwan J., Köhler L., Van Riel P., Vischer T. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002 Aug;61(8):718–722. doi: 10.1136/ard.61.8.718. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cawston T. Matrix metalloproteinases and TIMPs: properties and implications for the rheumatic diseases. Mol Med Today. 1998 Mar;4(3):130–137. doi: 10.1016/s1357-4310(97)01192-1. [DOI] [PubMed] [Google Scholar]
  6. Choy E. H. S., Isenberg D. A., Garrood T., Farrow S., Ioannou Y., Bird H., Cheung N., Williams B., Hazleman B., Price R. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 2002 Dec;46(12):3143–3150. doi: 10.1002/art.10623. [DOI] [PubMed] [Google Scholar]
  7. Corkill M. M., Gibson T., Panayi G. S. Pulse treatment with methylprednisolone in rheumatoid arthritis. BMJ. 1990 Sep 1;301(6749):446–446. doi: 10.1136/bmj.301.6749.446-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Houssiau F. A., Devogelaer J. P., Van Damme J., de Deuxchaisnes C. N., Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988 Jun;31(6):784–788. doi: 10.1002/art.1780310614. [DOI] [PubMed] [Google Scholar]
  9. Lipsky P. E., van der Heijde D. M., St Clair E. W., Furst D. E., Breedveld F. C., Kalden J. R., Smolen J. S., Weisman M., Emery P., Feldmann M. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000 Nov 30;343(22):1594–1602. doi: 10.1056/NEJM200011303432202. [DOI] [PubMed] [Google Scholar]
  10. Maini R., St Clair E. W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999 Dec 4;354(9194):1932–1939. doi: 10.1016/s0140-6736(99)05246-0. [DOI] [PubMed] [Google Scholar]
  11. Manicourt D. H., Fujimoto N., Obata K., Thonar E. J. Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation. Arthritis Rheum. 1995 Aug;38(8):1031–1039. doi: 10.1002/art.1780380803. [DOI] [PubMed] [Google Scholar]
  12. Moreland Larry W., O'Dell James R. Glucocorticoids and rheumatoid arthritis: back to the future? Arthritis Rheum. 2002 Oct;46(10):2553–2563. doi: 10.1002/art.10567. [DOI] [PubMed] [Google Scholar]
  13. Nossent H. C., Bakland G., Aslaksen H. K., Olsen G., Nordvåg B. Y. Efficacy of methylprednisolone pulse therapy versus infliximab in the treatment of severe flares of chronic polyarthritis. Scand J Rheumatol. 2001;30(6):335–339. doi: 10.1080/030097401317148525. [DOI] [PubMed] [Google Scholar]
  14. Radia M., Furst D. E. Comparison of three pulse methylprednisolone regimens in the treatment of rheumatoid arthritis. J Rheumatol. 1988 Feb;15(2):242–246. [PubMed] [Google Scholar]
  15. Ribbens C., Martin y Porras M., Franchimont N., Kaiser M-J, Jaspar J-M, Damas P., Houssiau F. A., Malaise M. G. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis. 2002 Feb;61(2):161–166. doi: 10.1136/ard.61.2.161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Smith M. D., Bertouch J. V., Smith A. M., Weatherall M., Ahern M. J., Brooks P. M., Roberts-Thomson P. J. The clinical and immunological effects of pulse methylprednisolone therapy in rheumatoid arthritis. I. Clinical effects. J Rheumatol. 1988 Feb;15(2):229–232. [PubMed] [Google Scholar]
  17. Vischer T. L., Sinniger M., Ott H., Gerster J. C. A randomized, double-blind trial comparing a pulse of 1000 with 250 mg methylprednisolone in rheumatoid arthritis. Clin Rheumatol. 1986 Sep;5(3):325–326. doi: 10.1007/BF02054249. [DOI] [PubMed] [Google Scholar]
  18. Weinblatt M. E., Kremer J. M., Bankhurst A. D., Bulpitt K. J., Fleischmann R. M., Fox R. I., Jackson C. G., Lange M., Burge D. J. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999 Jan 28;340(4):253–259. doi: 10.1056/NEJM199901283400401. [DOI] [PubMed] [Google Scholar]
  19. Weinblatt Michael E., Keystone Edward C., Furst Daniel E., Moreland Larry W., Weisman Michael H., Birbara Charles A., Teoh Leah A., Fischkoff Steven A., Chartash Elliot K. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003 Jan;48(1):35–45. doi: 10.1002/art.10697. [DOI] [PubMed] [Google Scholar]
  20. Weusten B. L., Jacobs J. W., Bijlsma J. W. Corticosteroid pulse therapy in active rheumatoid arthritis. Semin Arthritis Rheum. 1993 Dec;23(3):183–192. doi: 10.1016/s0049-0172(05)80039-3. [DOI] [PubMed] [Google Scholar]
  21. Wong P., Cuello C., Bertouch J. V., Roberts-Thomson P. J., Ahern M. J., Smith M. D., Youssef P. P. The effects of pulse methylprednisolone on matrix metalloproteinase and tissue inhibitor of metalloproteinase-1 expression in rheumatoid arthritis. Rheumatology (Oxford) 2000 Oct;39(10):1067–1073. doi: 10.1093/rheumatology/39.10.1067. [DOI] [PubMed] [Google Scholar]
  22. van der Veen M. J., Bijlsma J. W. The effect of methylprednisolone pulse therapy on methotrexate treatment of rheumatoid arthritis. Clin Rheumatol. 1993 Dec;12(4):500–505. doi: 10.1007/BF02231779. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES